Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02730377 · ClinicalTrials.gov registry record · Phase 4
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes
A Phase 4 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,991
- Enrollment target
NCT02730377: Completed Phase 4 study, sponsored by Novo Nordisk A/S.
NCT02730377 is a Phase 4 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 1,991 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (284% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02730377, a Phase 4 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,991 participants
- Enrollment target
Study Summary
This trial is conducted globally. The aim of the trial is to investigate efficacy in controlling glycaemia with Victoza® (liraglutide) as add-on to metformin background treatment vs. OADs as add-on to metformin background treatment for 104 weeks of treatment in subjects with type 2 diabetes.
Primary Outcome
Inadequate glycaemic control was defined as glycosylated haemoglobin (HbA1c) of 7.0% (53 mmol/mol) or greater at two consecutive visits after the first 26 weeks of treatment and up to 104 weeks. 25%, median (50%) and 75% percentiles for the cumulative distribution function, are obtained from the Kaplan-Meier survival function. HbA1c was recorded at weeks 38, 52, 65, 78, 91 and 104.
Interventions
- DRUG SGLT-2 inhibitors
- DRUG liraglutide
- DRUG alpha-glucosidase inhibitors
- DRUG DPP-4 inhibitors
- DRUG meglitinides
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,991 participants |
| Start Date | 2016-03-28 |
| Est. Completion | 2019-08-12 |
| Phase | Phase 4 |
What the finished NCT02730377 record still lists
NCT02730377 is an interventional study that assigns participants to a tested intervention. Its 1,991 participants enrollment target places it among the larger protocols in the corpus, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (284% higher).
The record links to 0 conditions, and to 5 interventions - of which SGLT-2 inhibitors is the first listed.
NCT02730377 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02730377 about?
NCT02730377 is a clinical study titled "Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes". This trial is conducted globally. The aim of the trial is to investigate efficacy in controlling glycaemia with Victoza® (liraglutide) as add-on to metformin background treatment vs. OADs as add-on to metformin background treatment for 104 weeks of treatment in subjects with type 2 diabetes.
What is the current status of trial NCT02730377?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,991 participants. The study started on 2016-03-28. Estimated completion is 2019-08-12.
What interventions are being tested in trial NCT02730377?
The interventions under investigation include: SGLT-2 inhibitors (DRUG), liraglutide (DRUG), alpha-glucosidase inhibitors (DRUG), DPP-4 inhibitors (DRUG), meglitinides (DRUG).
Who is sponsoring clinical trial NCT02730377?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02730377's enrollment target sits among peer trials
1,991 43rd of 2000 higher than 1,958 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
- NCT00001595 · 2,000 participants
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
- NCT00138931 · 2,000 participants
Genetics of Cardiovascular and Neuromuscular Disease
- NCT00288119 · 2,000 participants
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI